Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Dompe' Farmaceutici S P A is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by 1 distinct examiner and 1 distinct art unit, indicating that the company's current intellectual property efforts are highly centralized. In the pharmaceutical sector, such a focused prosecution profile often points to a specific biological innovation being examined by a single specialized group.
DONOGHUE, BRITTNEY ERIN is the busiest examiner for the company, overseeing 1 pending office action. Because the portfolio contains only 1 pending action in total, this examiner has exclusive oversight of the company's current patent pipeline. The 1 distinct art unit involved will dictate the procedural rules and timelines for this case. Consequently, the company's strategy must be tailored to the specific expectations of DONOGHUE, BRITTNEY ERIN, as there are no other active matters to balance the prosecution risk across different examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DONOGHUE, BRITTNEY ERIN | 1 | 58.8% | +46.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021979 | PEPTIDE FOR THERAPEUTIC APPLICATIONS IN THE DERMATOLOGICAL FIELD | DONOGHUE, BRITTNEY ERIN | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021979 | PEPTIDE FOR THERAPEUTIC APPLICATIONS IN THE DERMATOLOGICAL FIELD | DONOGHUE, BRITTNEY ERIN | 14d |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18021979 | PEPTIDE FOR THERAPEUTIC APPLICATIONS IN THE DERMATOLOGICAL FIELD | DONOGHUE, BRITTNEY ERIN | 1675 | §102§103 | Final Rejection | 14d | Pending | Feb 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial